Demographics and disease characteristics
. | All treated (N = 53) . | Secondary AML (N = 24) . |
---|---|---|
Median age, y (range) | 75 (60-87) | 77 (60-87) |
Sex, male, % | 64 | 75 |
ECOG, % | ||
0, | 19 | 13 |
1 | 79 | 88 |
MRC cytogenetic risk, % | ||
Favorable | 0 | 0 |
Intermediate | 62 | 25 |
Adverse | 38 | 75 |
Underlying myelodysplasia, % | 43 | 54 |
Baseline BM blast, %, median (range) | 52·5 (20-90) | 34 (20-90) |
Baseline WBC ×103/µL, median (range) | 2.1 (0.4-132) | 1.5 (0.8-18.9) |
. | All treated (N = 53) . | Secondary AML (N = 24) . |
---|---|---|
Median age, y (range) | 75 (60-87) | 77 (60-87) |
Sex, male, % | 64 | 75 |
ECOG, % | ||
0, | 19 | 13 |
1 | 79 | 88 |
MRC cytogenetic risk, % | ||
Favorable | 0 | 0 |
Intermediate | 62 | 25 |
Adverse | 38 | 75 |
Underlying myelodysplasia, % | 43 | 54 |
Baseline BM blast, %, median (range) | 52·5 (20-90) | 34 (20-90) |
Baseline WBC ×103/µL, median (range) | 2.1 (0.4-132) | 1.5 (0.8-18.9) |
BM, bone marrow; WBC, white blood count.